Clinical Trials Logo

Filter by:
NCT ID: NCT05653453 Not yet recruiting - Clinical trials for Locally Advanced Pancreatic Cancer

Clinical Study of Tumor Treating Fields Combined With Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer

Start date: December 20, 2022
Phase: Phase 3
Study type: Interventional

The Objectives of this clinical trial is to evaluate the efficacy and safety of tumor treating fields combined with gemcitabine and albumin bound paclitaxel in the treatment of locally advanced pancreatic cancer.

NCT ID: NCT05653427 Terminated - Clinical trials for Carcinoma, Hepatocellular

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Start date: December 8, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)

NCT ID: NCT05653349 Recruiting - Clinical trials for Primary Immune Thrombocytopenia (ITP)

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

VAYHIT1
Start date: March 6, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.

NCT ID: NCT05653219 Recruiting - Clinical trials for Primary Immune Thrombocytopenia

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

VAYHIT2
Start date: January 21, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.

NCT ID: NCT05653180 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Start date: March 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is designed to establish whether the combination of IBI310 & Sintilimab has efficacy in patients with advanced BTC

NCT ID: NCT05652920 Recruiting - Clinical trials for Hepatocellular Carcinoma

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Start date: December 15, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular Carcinoma(HCC).

NCT ID: NCT05652894 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer

Start date: December 20, 2022
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC).

NCT ID: NCT05652751 Recruiting - Ischemic Stroke Clinical Trials

Effect of EA Combined With NGF on Limb Function in Convalescent Patients With Ischemic Stroke

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Most ischemic stroke patients are in recovery phase, often accompanied by motor impairment, but they lack effective treatment. The appearance of nerve growth factor (NGF) promotes the development of neuroprotective therapy, but it has little effect on stroke because of the blood-brain barrier (BBB). Electroacupuncture (EA) has been used for stroke, while there is no significant clinical effect for recovery phrase. Consequently, we will conduct a multicentre, randomised, controlled, assessor-blinded clinical trial to assess the effectiveness and safety of EA combined with NGF treatment on ischemic stroke recovery.

NCT ID: NCT05652712 Recruiting - Lung Cancer Clinical Trials

A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)

Start date: January 1, 2019
Phase:
Study type: Observational

Our project is going to clarify the efficacy and safety of Toripalimab in lung cancer in the real world, and to evaluate the incidence of adverse events (AEs) of special interest during Toripalimab immunotherapy.

NCT ID: NCT05652621 Recruiting - Ulcerative Colitis Clinical Trials

Efficacy of Probiotics in Patients With IBD

Start date: July 31, 2022
Phase: N/A
Study type: Interventional

This research group plans to take patients with mild to moderate UC and diarrhea IBS diagnosed in the First Affiliated Hospital of Xinxiang Medical College as examples, and divide them into UC group and IBS group; Each group was randomly divided into two groups, namely, conventional treatment+probiotics group and conventional treatment+probiotics placebo group.Starting from the intervention of probiotics on intestinal flora to alleviate intestinal injury caused by UC and IBS patients, the indicators of intestinal flora, serum inflammatory factors, metabolites in vivo, intestinal barrier-related protein expression, and fecal short-chain fatty acid level were detected to explore the clinical efficacy, intestinal protective effect and mechanism of probiotics in adjuvant treatment of UC and IBS patients.To provide new methods and new ideas for refractory UC and IBS, so as to improve the cure rate of UC and IBS, reduce the recurrence rate, relieve the physical and mental pain and economic burden of patients, and provide new ideas for the development and utilization of functional probiotics. It also seeks biosafety evidence for the future use of probiotics in antibiotic environment.